Table 2.
Annual incidence rates of hepatocellular carcinoma, decompensation and death/transplantation according to treatment exposure and the presence of cirrhosis
|
|
Group
|
PY
|
No. of events
|
No./100 PY (95%CI)
|
HR (95%CI)
|
P
value
|
| Entire cohort | Hepatocellular carcinoma | |||||
| Untreated group | 3285.4 | 65 | 1.98 (1.56-2.52) | Reference | - | |
| IBT group | 3888.9 | 23 | 0.59 (0.39-0.89) | 0.31 (0.19-0.49) | < 0.001 | |
| DAA group | 2158.0 | 25 | 1.16 (0.78-1.71) | 0.59 (0.37-0.95) | 0.029 | |
| Decompensation | ||||||
| Untreated group | 3333.6 | 54 | 1.62 (1.24-2.11) | Reference | - | |
| IBT group | 3950.1 | 10 | 0.25 (0.14-0.47) | 0.15 (0.07-0.29) | < 0.001 | |
| DAA group | 2178.7 | 5 | 0.23 (0.10-0.55) | 0.16 (0.06-0.39) | < 0.001 | |
| Death or transplantation | ||||||
| Untreated group | 4438.3 | 148 | 3.33 (2.85-3.91) | Reference | - | |
| IBT group | 4850.1 | 42 | 0.87 (0.64-1.18) | 0.22 (0.16-0.31) | < 0.001 | |
| DAA group | 2467.2 | 16 | 0.65 (0.40-1.06) | 0.30 (0.17-0.51) | < 0.001 | |
| No cirrhosis | Hepatocellular carcinoma | |||||
| Untreated group | 2364.6 | 15 | 0.63 (0.38-1.05) | Reference | - | |
| IBT group | 2971.8 | 6 | 0.20 (0.09-0.45) | 0.30 (0.11-0.77) | 0.012 | |
| DAA group | 1569.4 | 8 | 0.51 (0.26-1.02) | 0.90 (0.37-2.18) | 0.812 | |
| Decompensation | ||||||
| Untreated group | 2369.9 | 6 | 0.25 (0.11-0.56) | Reference | - | |
| IBT group | 2992.3 | 1 | 0.03 (0.00-0.24) | 0.09 (0.01-0.74) | 0.026 | |
| DAA group | 1573.4 | 0 | 0.00 | 0.00 | N/A | |
| Death or transplantation | ||||||
| Untreated group | 3176.3 | 63 | 1.98 (4.15-7.12) | Reference | - | |
| IBT group | 3712.3 | 22 | 0.59 (0.39-0.90) | 0.26 (0.16-0.42) | < 0.001 | |
| DAA group | 1784.6 | 7 | 0.39 (0.19-0.82) | 0.33 (0.15-0.75) | 0.008 | |
| Cirrhosis | Hepatocellular carcinoma | |||||
| Untreated group | 919.9 | 50 | 5.44 (4.15-7.12) | Reference | - | |
| IBT group | 917.1 | 17 | 1.85 (1.16-2.97) | 0.35 (0.20-0.61) | < 0.001 | |
| DAA group | 588.6 | 17 | 2.89 (1.81-4.61) | 0.53 (0.30-0.92) | 0.025 | |
| Decompensation | ||||||
| Untreated group | 962.8 | 48 | 4.99 (3.78-6.57) | Reference | - | |
| IBT group | 957.7 | 9 | 0.84 (0.49-1.80) | 0.18 (0.09-0.37) | < 0.001 | |
| DAA group | 606.3 | 5 | 0.82 (0.34-1.97) | 0.17 (0.07-0.44) | < 0.001 | |
| Death or transplantation | ||||||
| Untreated group | 1262.1 | 85 | 6.73 (5.48-8.27) | Reference | - | |
| IBT group | 1137.8 | 20 | 1.76 (1.14-2.71) | 0.21 (0.13-0.35) | < 0.001 | |
| DAA group | 682.6 | 9 | 1.32 (0.69-2.52) | 0.28 (0.14-0.56) | < 0.001 | |
A Cox proportional hazards model was used to determine hazards ratios and P values. CI: Confidence interval; DAA: Direct acting antivirals; HR: Hazard ratio; IBT: Interferon-based therapy; N/A: Not applicable; PY: Person-year.